Click the blue text Follow us This Issue Highlights In recent years, the field of tumor immunotherapy has welcomed an important new target—DLL3. As a ligand of the Notch signaling pathway, DLL3 (Delta-like ligand 3) plays a key role in the progression of various malignant tumors, particularly in small cell lung cancer (SCLC) and neuroendocrine … Read more
Hello everyone, today I will introduce an article published in Nature Communications titled “Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapy.” The corresponding authors of this article are Dr. Xu Chen and Professor Tianxin Lin from Sun Yat-sen University Affiliated Sun Yat-sen Memorial Hospital, whose main research directions include … Read more
Key Points 1 For patients with muscle-invasive bladder cancer (MIBC) who are not suitable for cisplatin treatment, sacituzumab govitecan and pembrolizumab show promise as alternatives to radical cystectomy, with a clinical complete response rate (cCR) of 44.4%. 2 The SURE-02 trial emphasizes bladder preservation, adjusting treatment plans based on patient preferences and treatment responses, shifting … Read more
The Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in collaboration with Researcher Hai Jun and Professor Xu Zhi’ai from the School of Chemistry and Molecular Engineering at East China Normal University, has developed a novel LNP component—ultrasound adjuvant lipids, which endow clinically approved LNP formulations with region-specific adjuvant properties. mRNA vaccines based on … Read more
Click the blue text Follow us This issue Highlights of At the 2025 WCLC, Junshi Biosciences unveiled the groundbreaking phase I clinical data of its PD-L1 ADC (HLX43), attracting widespread attention in the industry. As the next frontier in the field of immune checkpoint inhibitors, PD-L1 ADC integrates the “dual strike” mechanism of immunotherapy and … Read more
Click the blue text above to follow for more exciting content What is CAR-T Cell Therapy? CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a type of immunotherapy primarily used for the clinical treatment of malignant blood diseases and tumors. CAR-T therapy involves collecting and isolating T cells from the patient’s blood, followed by genetic … Read more
Author | Xiao Yu Periodically, major pharmaceutical media and authoritative journals summarize the development of Antibody-Drug Conjugates (ADCs). Recently, a review on ADCs published by the internationally renowned journal ACS was particularly eye-catching. As a member of CAS (a division of the American Chemical Society), Janet M. Sasso’s team innovatively utilized patents and articles related … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that it is possible to find and develop drugs that specifically target the unique structural features of pathogens, killing only the pathogens without affecting normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target … Read more
Source: Beike Society Antibody-drug conjugates (ADCs) have become a popular avenue in tumor treatment in recent years, typically covalently linking a monoclonal antibody (mAb) to a cytotoxic drug (payload) via a chemically synthesized linker. ADCs combine the advantages of highly specific targeting capabilities with potent killing effects, achieving precise and efficient elimination of cancer cells. … Read more
This conference is themed “Innovative Processes, Achieving the Future of the Pharmaceutical Industry,” featuring one keynote session and three parallel sessions, gathering over 50 professional speakers from the fields of antibodies, ADCs, GLP-1, and peptides. It focuses on downstream processes and advanced separation and purification techniques, discussing the future of the pharmaceutical industry! Known as … Read more